200 related articles for article (PubMed ID: 20813009)
1. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells.
Choudhury A; Derkow K; Daneshmanesh AH; Mikaelsson E; Kiaii S; Kokhaei P; Osterborg A; Mellstedt H
Br J Haematol; 2010 Nov; 151(4):327-35. PubMed ID: 20813009
[TBL] [Abstract][Full Text] [Related]
2. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Moosmann A; Kofler DM; Hallek M; Wendtner CM
Blood; 2005 Feb; 105(4):1566-73. PubMed ID: 15471955
[TBL] [Abstract][Full Text] [Related]
3. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).
Uhrmacher S; Schmidt C; Erdfelder F; Poll-Wolbeck SJ; Gehrke I; Hallek M; Kreuzer KA
Leuk Res; 2011 Oct; 35(10):1360-6. PubMed ID: 21531460
[TBL] [Abstract][Full Text] [Related]
4. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.
Li P; Harris D; Liu Z; Liu J; Keating M; Estrov Z
PLoS One; 2010 Jul; 5(7):e11859. PubMed ID: 20686606
[TBL] [Abstract][Full Text] [Related]
5. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.
Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
PLoS One; 2013; 8(10):e78339. PubMed ID: 24205204
[TBL] [Abstract][Full Text] [Related]
6. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.
Daneshmanesh AH; Mikaelsson E; Jeddi-Tehrani M; Bayat AA; Ghods R; Ostadkarampour M; Akhondi M; Lagercrantz S; Larsson C; Osterborg A; Shokri F; Mellstedt H; Rabbani H
Int J Cancer; 2008 Sep; 123(5):1190-5. PubMed ID: 18546292
[TBL] [Abstract][Full Text] [Related]
7. ROR1 expression is not a unique marker of CLL.
Barna G; Mihalik R; Timár B; Tömböl J; Csende Z; Sebestyén A; Bödör C; Csernus B; Reiniger L; Peták I; Matolcsy A
Hematol Oncol; 2011 Mar; 29(1):17-21. PubMed ID: 20597086
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi AR; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
Leukemia; 2012 Jun; 26(6):1348-55. PubMed ID: 22289919
[TBL] [Abstract][Full Text] [Related]
9.
Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
[TBL] [Abstract][Full Text] [Related]
10. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
Hasan MK; Ghia EM; Rassenti LZ; Widhopf GF; Kipps TJ
Leukemia; 2021 Jun; 35(6):1621-1630. PubMed ID: 33097837
[TBL] [Abstract][Full Text] [Related]
11. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.
Giannopoulos K; Li L; Bojarska-Junak A; Rolinski J; Dmoszynska A; Hus I; Greiner J; Renner C; Döhner H; Schmitt M
Int J Oncol; 2006 Jul; 29(1):95-103. PubMed ID: 16773189
[TBL] [Abstract][Full Text] [Related]
12. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
Baskar S; Kwong KY; Hofer T; Levy JM; Kennedy MG; Lee E; Staudt LM; Wilson WH; Wiestner A; Rader C
Clin Cancer Res; 2008 Jan; 14(2):396-404. PubMed ID: 18223214
[TBL] [Abstract][Full Text] [Related]
13. Post-translational modifications regulate signalling by Ror1.
Kaucká M; Krejčí P; Plevová K; Pavlová S; Procházková J; Janovská P; Valnohová J; Kozubík A; Pospíšilová S; Bryja V
Acta Physiol (Oxf); 2011 Nov; 203(3):351-62. PubMed ID: 21481194
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.
Hojjat-Farsangi M; Ghaemimanesh F; Daneshmanesh AH; Bayat AA; Mahmoudian J; Jeddi-Tehrani M; Rabbani H; Mellstedt H
PLoS One; 2013; 8(4):e61167. PubMed ID: 23593420
[TBL] [Abstract][Full Text] [Related]
15. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
[TBL] [Abstract][Full Text] [Related]
16. Anchored Fibromodulin as a Novel Target in Chronic Lymphocytic Leukemia: Diagnostic and Therapeutic Implications.
Farahi L; Ghaemimanesh F; Milani S; Razavi SM; Hadavi R; Bayat AA; Salimi A; Akhondi MM; Rabbani H
Iran J Immunol; 2019 Jun; 16(2):127-141. PubMed ID: 31182687
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
PLoS One; 2015; 10(11):e0142310. PubMed ID: 26562161
[TBL] [Abstract][Full Text] [Related]
18. A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes.
McCarthy BA; Yancopoulos S; Tipping M; Yan XJ; Wang XP; Bennett F; Li W; Lesser M; Paul S; Boyle E; Moreno C; Catera R; Messmer BT; Cutrona G; Ferrarini M; Kolitz JE; Allen SL; Rai KR; Rawstron AC; Chiorazzi N
Immunol Res; 2015 Dec; 63(1-3):90-100. PubMed ID: 26318878
[TBL] [Abstract][Full Text] [Related]
19. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.
Cui B; Ghia EM; Chen L; Rassenti LZ; DeBoever C; Widhopf GF; Yu J; Neuberg DS; Wierda WG; Rai KR; Kay NE; Brown JR; Jones JA; Gribben JG; Frazer KA; Kipps TJ
Blood; 2016 Dec; 128(25):2931-2940. PubMed ID: 27815263
[TBL] [Abstract][Full Text] [Related]
20. Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia.
Khan AS; Hojjat-Farsangi M; Daneshmanesh AH; Hansson L; Kokhaei P; Österborg A; Mellstedt H; Moshfegh A
Tumour Biol; 2016 Sep; 37(9):11947-11957. PubMed ID: 27086035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
